Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.
Los Angeles Times - December 19 2001
From Times Staff and Wire Reports
The study is the first large-scale national survey to reveal the drug resistance. Previous drug-resistance research, physicians said, focused only on smaller groups of patients.
"This is very discouraging," said Dr. Samuel Bozette of the San Diego VA Medical Center, a co-leader of the study. "It really shows the breadth of the problem.
This is something we'll have to take into account in future treatment plans and strategies." The survey, coordinated by the Rand Corp. think tank in Santa Monica, tested blood samples of about 1,700 patients. More than three-quarters showed signs of resistance to one or more drugs frequently used to treat HIV.
About 85% of the patients who were prescribed the type of therapy that often includes "cocktails" of three or more drugs had drug resistant strains of HIV.
In the past, many researchers believed the poor, the homeless and intravenous drug users were most likely to have resistant viruses because they might not properly use AIDS drugs. But this study revealed that "white males . . . , those with higher education and private medical insurance" were most likely to have drug-resistant viruses. Researchers also emphasized that drug-resistant strains of HIV can be transmitted by sexual contact.
Related studies have revealed that up to 20% of newly diagnosed HIV patients--even before they are prescribed drugs--have a strain of HIV that is drug-resistant, said Dr. Douglas Richman of UC San Diego, a co-leader of the study.
"We need to step up efforts to prevent transmission of drug-resistant virus, as this appears to be an increasing problem," he said.
Researchers were surprised by the study's numbers, which show the need for testing to reveal the specific drugs that won't work for the patient.
"There needs to be more use of drug resistance testing to manage patients who have failed treatment and who have been recently infected . . . ," Richman said.
"We need new drugs that are effective against drug-resistant virus."
Researchers have found that unless HIV is completely suppressed, a resistance can develop, Bozette said. As a result, doctors have to be particularly careful about prescribing the right combination of drugs.
"Unless you knock out the virus completely, it will continue to multiply," Bozette said. "And that virus that multiplies is just the strain that will be resistant to the drugs you're taking."
011219
LT011208
Copyright © 2001 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .